NewEdge Advisors’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.48M | Buy |
39,462
+621
| +2% | +$117K | 0.02% | 605 |
|
|
2026
Q1 | $7.66M | Sell |
38,841
-6,065
| -14% | -$1.17M | 0.03% | 532 |
|
|
2025
Q4 | $8.26M | Buy |
44,906
+13,329
| +42% | +$2.34M | 0.03% | 497 |
|
|
2025
Q3 | $4.85M | Sell |
31,577
-5,246
| -14% | -$794K | 0.02% | 643 |
|
|
2025
Q2 | $5.15M | Sell |
36,823
-118
| -0.3% | -$16.5K | 0.03% | 562 |
|
|
2025
Q1 | $5.43M | Buy |
36,941
+707
| +2% | +$102K | 0.03% | 482 |
|
|
2024
Q4 | $4.75M | Buy |
36,234
+8,860
| +32% | +$1.24M | 0.03% | 515 |
|
|
2024
Q3 | $4.27M | Buy |
27,374
+2,579
| +10% | +$416K | 0.03% | 535 |
|
|
2024
Q2 | $3.87M | Buy |
24,795
+2,890
| +13% | +$435K | 0.03% | 528 |
|
|
2024
Q1 | $2.97M | Buy |
21,905
+2,979
| +16% | +$394K | 0.03% | 550 |
|
|
2023
Q4 | $2.54M | Buy |
18,926
+1,713
| +10% | +$223K | 0.02% | 582 |
|
|
2023
Q3 | $2.33M | Buy |
17,213
+1,501
| +10% | +$205K | 0.03% | 554 |
|
|
2023
Q2 | $2.25M | Sell |
15,712
-585
| -4% | -$86.1K | 0.03% | 550 |
|
|
2023
Q1 | $2.26M | Sell |
16,297
-472
| -3% | -$63.5K | 0.03% | 497 |
|
|
2022
Q4 | $491K | Buy |
16,769
+929
| +6% | +$117K | 0.01% | 783 |
|
|
2022
Q3 | $1.74M | Buy |
15,840
+8
| +0.1% | +$1.01K | 0.03% | 466 |
|
|
2022
Q2 | $2.09M | Sell |
15,832
-8,221
| -34% | -$1.08M | 0.03% | 426 |
|
|
2022
Q1 | $3.19M | Buy |
24,053
+1,313
| +6% | +$157K | 0.05% | 323 |
|
|
2021
Q4 | $2.65M | Buy |
22,740
+565
| +3% | +$66.5K | 0.04% | 372 |
|
|
2021
Q3 | $2.66M | Sell |
22,175
-5,797
| -21% | -$675K | 0.07% | 266 |
|
|
2021
Q2 | $3.35M | Sell |
27,972
-1,517
| -5% | -$166K | 0.09% | 221 |
|
|
2021
Q1 | $2.93M | Sell |
29,489
-132,048
| -82% | -$13.3M | 0.09% | 220 |
|
|
2020
Q4 | $16.1M | Buy |
161,537
+154,477
| +2,188% | +$16.4M | 0.53% | 46 |
|
|
2020
Q3 | $774K | Buy |
+7,060
| New | +$785K | 0.03% | 451 |
|
|
2020
Q1 | – | Sell |
-2,457
| Closed | -$245K | – | 799 |
|
|
2019
Q4 | $245K | Sell |
2,457
-182
| -7% | -$17.1K | 0.01% | 719 |
|
|
2019
Q3 | $233K | Buy |
+2,639
| New | +$229K | 0.01% | 705 |
|
|
2017
Q3 | – | Sell |
-364
| Closed | -$24.4K | – | 421 |
|
|
2017
Q2 | $24.4K | Buy |
+364
| New | +$23.8K | ﹤0.01% | 677 |
|
Other funds holding AZN
EPGL
VCM
VAM
VFT
NewEdge Advisors's AZN Position: Q2 2026 in Review
NewEdge Advisors increased its AstraZeneca (AZN) stake by 1.6% in Q2 2026, buying an estimated $117K and bringing the position to 39,462 shares worth $7.48M. The position accounts for 0.02% of the portfolio, ranked #605.
NewEdge Advisors first reported a position in AZN in Q2 2017 and has held it in 27 quarters since. The position peaked at $16.1M in Q4 2020. 1,253 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- NewEdge Advisors held 39,462 shares of AstraZeneca worth $7.48M as of Q2 2026.
- NewEdge Advisors bought 621 AstraZeneca shares in Q2 2026, an estimated $117K.
- AstraZeneca made up 0.02% of NewEdge Advisors's portfolio in Q2 2026, its #605 holding.
- NewEdge Advisors first reported a position in AstraZeneca in Q2 2017 and has held it in 27 quarters since.
- NewEdge Advisors's AstraZeneca position peaked at $16.1M in Q4 2020.
- 1,253 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.